{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:34:07Z","timestamp":1778070847953,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.autrev.2023.103463","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:17:57Z","timestamp":1697296677000},"page":"103463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Should we use nintedanib as early therapy in patients with SSc-ILD?"],"prefix":"10.1016","volume":"23","author":[{"given":"Elisabetta","family":"Zanatta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Moccaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Szucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.autrev.2023.103463_bb0005","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.autrev.2023.103463_bb0010","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.autrev.2023.103463_bb0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/23971983211064463","article-title":"Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography","volume":"7","author":"Khanna","year":"2022","journal-title":"J. Scleroderma. Relat. Disord."},{"issue":"9","key":"10.1016\/j.autrev.2023.103463_bb0020","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2023.103463_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.autrev.2023.103463_bb0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.chest.2021.11.033","article-title":"Early radiographic progression of scleroderma: lung disease predicts long-term mortality","volume":"161","author":"Volkmann","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002850","article-title":"Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study","volume":"9","author":"Campochiaro","year":"2023","journal-title":"RMD Open."},{"issue":"3","key":"10.1016\/j.autrev.2023.103463_bb0040","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12016-022-08926-0","article-title":"Thoracic involvement in systemic autoimmune rheumatic diseases: pathogenesis and management","volume":"63","author":"De Zorzi","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"12","key":"10.1016\/j.autrev.2023.103463_bb0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease--mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"26","key":"10.1016\/j.autrev.2023.103463_bb0050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.autrev.2023.103463_bb0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.autrev.2023.103463_bb0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open. Rheumatol."},{"issue":"12","key":"10.1016\/j.autrev.2023.103463_bb0065","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.autrev.2023.103463_bb0070","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.chest.2022.09.044","article-title":"Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from European scleroderma trials and research","volume":"163","author":"Hoffmann-Vold","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.autrev.2023.103463_bb0075","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.autrev.2023.103463_bb0080","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103463_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified rodnan skin thickness score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheum."},{"issue":"18","key":"10.1016\/j.autrev.2023.103463_bb0090","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.autrev.2023.103463_bb0095","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.autrev.2023.103463_bb0100","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1093\/rheumatology\/keab273","article-title":"Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients","volume":"60","author":"Suleman","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open."},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.autrev.2023.103463_bb0120","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.autrev.2023.103463_bb0125","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1378\/chest.13-3014","article-title":"Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry","volume":"146","author":"Chung","year":"2014","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.autrev.2023.103463_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/1744666X.2018.1427064","article-title":"Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy","volume":"14","author":"George","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103463_bb0135","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2023.103463_bb0140","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"25","key":"10.1016\/j.autrev.2023.103463_bb0145","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.autrev.2023.103463_bb0150","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2023.103463_bb0155","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the scleroderma lung study III [abstract] arthritis","volume":"74","author":"Khanna","year":"2022","journal-title":"Rheumatol."},{"issue":"10038","key":"10.1016\/j.autrev.2023.103463_bb0160","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2023.103463_bb0165","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.autrev.2023.103463_bb0175","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European scleroderma trials and research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2 Suppl","key":"10.1016\/j.autrev.2023.103463_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J. Scleroderma. Relat. Disord."},{"issue":"1","key":"10.1016\/j.autrev.2023.103463_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2023.103463_bb0190","first-page":"1","article-title":"Systemic sclerosis","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"10.1016\/j.autrev.2023.103463_bb0195","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.autrev.2023.103463_bb0200","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2665-9913(22)00215-6","article-title":"Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials","volume":"4","author":"Hoffmann-Vold","year":"2022","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2023.103463_bb0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T07:23:06Z","timestamp":1712301786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1568997223001970"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103463","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we use nintedanib as early therapy in patients with SSc-ILD?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103463"}}